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Comparison of Five Methods for Detection of Extended Spectrum β-Lactamases
-Lactamases
in Gram Negative Enteric Bacteria
Abstract
The presence of extended-spectrum β-lactamases in 55 isolates of Gram negative enteric bacteria
isolated from lower respiratory tract infections, was investigated by using the Clinical Laboratory
Standards Institute CLSI method which showed that 41.8% of the isolates produced this type of βlactamases, and that Klebsiella pneumoniae isolates were the most producing species with a production
rate of 61.1%, followed by Escherichia coli isolates 43.75%. Five confirmatory methods were used to
detect these enzymes: ceftazidime agar method, double-disk synergy method, combination disk method,
modified 3D extract method and enzymatic disks method. The study indicated that ceftazidime agar
method was the best method in detecting extended-spectrum β-lactamases as it gave a detection rate of
95.7%, followed by the double-disk synergy method with a rate of 87%, then enzymatic disks method with
a rate of 73.9%.
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1. Introduction
Gram negative enteric bacteria represented by
Enterobacteriaceae and Pseudomonas aeruginosa are
one of the most antibiotic-resistant bacteria, especially
to b-lactams [1,2]. As these species are opportunistic
pathogens and common causes of hospital-acquired
infections, their possession to such resistance to
various b-lactams including broad spectrum ones increases their virulence and resistance to treatment,
which makes infections caused by these bacteria more
serious and sometimes life-threatening [3e5].
Bacterial species resist b-lactam antibiotics using
different mechanisms, but the most common, important
and widespread mechanism are b-lactamase enzymes,
which act by opening the b-lactam ring necessary for the
effectiveness of the antibiotics, thus posing a serious
threat to the use of these antibiotics in treating infections
caused by the bacteria producing these enzymes,
particularly Gram-negative enteric bacilli [6e10].
Extended-spectrum b-lactamases ESBLs (serine
enzymes of molecular class A) are the most common
types of these enzymes, and are characterized by their
ability to hydrolyze the third generation cephalosporins
as well as the penicillins and early cephalosporins, but
they remain sensitive to cephamycins, and they
inhibited by clavulanic acid, which is often used in the
detection of ESBL-producing bacteria [11e15].
The importance of these enzymes increases with the
increase of their number and the persistence of the
emergence of new types of them, noteworthy plasmidmediated ESBLs has contributed to the widespread
dissemination of ESBLs among different bacterial species all over the world [16e18]. As well, the large number
of b-lactam drugs and the uncontrolled usage of them
often assist in the selection of resistant bacterial strains
under the influence of selective pressure [19e21].
Therefore, the present study aimed to investigate the
presence of extended-spectrum b-lactamase enzymes
in some Gram-negative bacterial species in more than
one method and determine the most efficient method or
methods.
2. Materials and methods
2.1. Bacterial isolates
Fifty five clinical bacterial isolates of Gram negative enteric bacteria isolated from lower respiratory

tract infections in Mosul city were used. Isolation and
identification of isolates were done according to their
morphology, Gram stain, cultural and biochemical
characteristics [22,23]. Table 1 shows the bacterial
species used and their numbers.
2.2. Preparation of crude enzymatic extracts
Fresh bacterial suspensions were prepared in trypton soy broth and incubated for 4 h at 35  C. The cells
were precipitated using a cooled centrifuge at a speed
of 19470 g for 15 min and washed three-times with
phosphate buffer saline. The precipitant was suspended
in a solution of 0.2 M Sodium acetate (pH 5.5) and
subjected to seven cycles of freezing and thawing
[24e26]. The supernatant was obtained using a cooled
centrifuge (19470 g) for 30 min. The extracts were
kept at a temperature of 20  C until they were used in
the detection tests.
2.3. Detection of ESBLs using CLSI method
2.3.1. Initial screening test
Bacterial suspensions equivalent in turbidity to tube
No. 0.5 of McFarland standards were prepared, inoculated on Mueller-Hinton agar as recommended by
CLSI. Cefpodoxime, ceftriaxone, cefotaxime ceftazidime, and aztreonam disks were distributed on the
surface of the agar, and incubated at 35  C for 18-16 h.
After the incubation period, the diameter of the inhibition zones were measured and compared with the
CLSI table for this test. The isolates that gave a positive result for this test were confirmed by the phenotypic confirmatory test [27].

Table 1
Bacterial species used in the study.
Bacterial species

No. of isolates

Klebsiella pneumoniae
Escherichia coli
Pseudomonas aeruginosa
Serratia marcescens
Enterobacter aerogenes
Enterobacter cloacae
Proteus mirabilis
Total

18
16
14
2
3
1
1
55
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2.3.2. Phenotypic confirmatory test
The test was performed as recommended by CLSI.
Mueller-Hinton agar plates were inoculated with fresh
bacterial suspensions, and the following disks were
distributed: ceftazidime, ceftazidime/clavulanic acid,
cefotaxime, cefotaxime/clavulanic acid. After incubation at 35  C for 18-16 h, the diameter of the inhibition
zones was measured. An increase in the diameter of the
inhibition zone (5 mm and more) in the case of antibiotic with clavulanic acid compared to its diameter in
the case of antibiotic alone was considered as an
indication of the presence of ESBLs [27e29].
2.4. Double disk synergy method
In this method, amoxicillin-clavulanic acid disk was
placed in the center of inoculated Mueller-Hinton agar
plates, Cefotaxime and Ceftazidime disks were placed
20e30 mm from the central disk. The plates were
incubated at 35  C for 18-16 h. The expansion of the
inhibition zone towards amoxicillin-clavulanic acid
disk was considered as evidence of ESBLs presence
[30,31].
2.5. The combination disk method
Cefpodoxime 10 mg/disk was used in this method.
The diameter of the inhibition zone given by this
antibiotic is compared with that given by the same
antimicrobial plus clavulanic acid at a concentration of
1 mg/disk. Bacterial isolate will be considered as a
producer of ESBLs if the diameter of the inhibition
zone in the presence of clavulanic acid has an increase
equal to or greater than 5 mm than in its absence
[32e34]. Because of the absence of ready-made disks
containing cefpodoxime with clavulanic acid, a modification to the method was made by placing an
amoxicillin-clavulanic acid disk, as a source of clavulanic acid, 20e30 mm from cefpodoxime disk, plates
were incubated at 35  C for 16e18 h, after which zone
expansion was detected.
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growth in the region where the slit intersects with the
inhibition zone is an affirmative evidence of the
occurrence of ESBLs in the isolate [24,35,36].
2.7. Ceftazidime agar method
Ceftazidime was added to Mueller-Hinton agar with
a concentration of 4 mg/ml. Plates were inoculated with
ceftazidime-sensitive isolate, after that wells were
made with a diameter of 5 mm, to which 30 mlywell
of the crude enzymatic extracts were added. Plates
were incubated at 35  C for 16e18 h. The growth of
the sensitive isolate around any of the wells is evidence
of the presence of ESBLs in the enzymatic extract
[6,37].
2.8. Enzymatic disks method
Mueller-Hinton agar plate was inoculated with a
ceftazidime-sensitive isolate, and then a ceftazidime
disk was placed in the center of the plate surrounded
by disks with crude enzymatic extracts at a distance of
20e25 mm from the central disk. Plates were incubated at 35  C for 16e18 h. The result was recorded by
the emergence of growth around the enzymatic extract
disks within the inhibition zone, which was considered
as an evidence of the presence of ESBLs (ceftazidimases), which allowed the sensitive isolate to grow.
3. Results
3.1. Detection of ESBLs using CLSI method
Extended spectrum b-lactamases were detected according to the CLSI recommendations where initial
screening test and phenotypic confirmatory test were
performed (Fig. 1). Out of 55 clinical isolates 23
(41.8%) gave positive result. Klebsiella pneumoniae
isolates had the highest percentage, while other species
varied in possessing these enzymes and some gave
negative results (Table 2).

2.6. Modified three dimensional extract method

3.2. Detection of ESBLs using confirmatory methods

Mueller-Hinton agar plate was inoculated with
ceftazidime-sensitive isolate, and then a ceftazidime
disk was placed in the center of the plate. Four slits
were made in the agar using a sterile scalpel starting at
a distance of 5 mm from the edge of the disc toward
the edge of the plate. Thirty microliters of crude
enzymatic extracts were added to each slit, plates were
incubated at 35  C for 16e18 h. The emergence of

In the present study, five additional methods were
used to confirm the results of CLSI method in detecting
ESBLs production in Gram negative enteric bacteria.
These tests were performed on 23 isolates that gave
positive results for the CLSI method (Table 2).
Table 3 shows the results of these tests in comparison to CLSI method, where ceftazidime agar method
gave the best detection percentage (95.7%) in
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Fig. 1. Detection of ESBLs using CLSI method. Right plate: Initial screening test. Disks from above clockwise: Aztreonam, Ceftriaxone,
Cefpodoxime, Ceftazidime, Cefotaxime. Left plate: Phenotypic confirmatory test. Disks from above left clockwise: Ceftazidime, Ceftazidime/
Clavulanic acid, Cefotaxime, Cefotaxime/Clavulanic acid.

Table 2
ESBLs production percentages using CLSI method.

4. Discussion

Bacterial species

Number of tested
isolates

Positive isolates
No. (%)

K.pneumoniae
E.coli
P.aeruginosa
S.marcescens
E.aerogenes
E.cloacae
Pr.mirabilis
Total

18
16
14
2
3
1
1
55

11 (61.1)
7 (43.75)
4 (28.6)
1 (50)
0 (0)
0 (0)
0 (0)
23 (41.8)a

a

Positive isolates were selected for confirmatory detection
methods.

comparison to CLSI method, followed by double disk
synergy method (87%), and enzymatic disks method
(73.9%), while both the combination disk method and
the modified three-dimensional extract method had the
lowest percentage (56.5% for each) as depicted in Figs.
2e5.

Most of the Gram-negative enteric bacteria have at
least one of the b-lactamases that protects them from
the lethal action of b-lactam antibiotics. Some of these
bacteria may have several types of these enzymes that
differ in their properties and spectrum of antimicrobials they work on, which give them an advantage over
other bacteria [16,18].
Extended spectrum b-lactamases are major group of
b-lactamases that are responsible for the worldwide
bacterial resistance to b-lactam antibiotics especially
in Gram negative enteric bacteria, which makes the
detection of these enzymes of significant importance
for proper treatment to achieve and bacterial resistance
to defeat [1,21]. Therefore, our study concentrated on
the detection methods developed and used for
screening bacterial isolates for ESBLs production in
order to investigate their efficiency and determine the
best method in comparison to the CLSI method.

Table 3
ESBLs production percentages using confirmatory methods.
Bacterial
species
P.aeruginosa
K.pneumoniae
E.coli
S.marcescens
Total

Isolates
tested

Positive isolates NO. (%)
CLSI
method

Double disk
synergy method

Combination disk
method

Modified 3D
extract method

Ceftazidime agar
method

Enzymatic disk
method

4
11
7
1
23

4 (100)
11 (100)
7 (100)
1 (100)
23 (100)

3 (75)
10 (90.9)
6 (85.7)
1 (100)
20 (87)

1 (25)
7 (63.6)
5 (71.4)
0 (0)
13 (56.5)

2 (50)
6 (54.6)
5 (71.4)
0 (0)
13 (56.5)

3 (75)
11 (100)
7 (100)
1 (100)
22 (95.7)

2 (50)
9 (81.8)
6 (85.7)
0 (0)
17 (73.9)
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Fig. 4. Detection of ESBLs using modified 3D extract method.
Fig. 2. Detection of ESBLs using double disk synergy method.

We found that out of 55 isolates tested by CLSI
method 23 (41.8%) gave positive results, and that K.
pneumoniae isolates had the highest percentage, followed by Escherichia coli, P. aeruginosa, Serratia
marcescens (see Table 2). These results indicated the
high production of ESBLs enzymes by these species,
which are in agreement with many studies and researches including CLSI documents [6e8,10,27,38],
which clearly stated the importance and significance of
these enzymes as they represent a real threat to
infection treatment with b-lactams, especially if we
consider that these enzymes almost been plasmidmediated with high dissemination capabilities to other
species.

Extended-spectrum b -lactamase production rates
vary between bacterial species as well as between
different countries. Also, the antibiotics amount used
plays an important role in determining these rates and
selecting resistant strains, as well as the occurrence of
R-plasmids. It is crucial to prescribe b elactam antibiotics (especially new ones) only after confirming the
sensitivity of the pathogenic bacteria in order to reduce
the spread of resistant strains, with the importance of
testing bacteria for ESBLs production and not just for
traditional sensitivity tests, where CLSI recommendations indicate that ESBLs-positive isolates must be
recorded as resistant to all third generation cephalosporins, as well as for aztreonam, and it is not recommended to give these antibiotics as a treatment

Fig. 3. Detection of ESBLs using combination disk method.

Fig. 5. Detection of ESBLs using ceftazidime agar method.
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regardless of the results of traditional sensitivity tests
[16,27].
It is noteworthy that some bacterial isolates may
have several enzymes of more than one type of blactamases, these enzymes may differ from each other
in their inhibitory properties and substrate profile
[10,18,39]. Thus, when conducting detection tests, the
properties of some of these enzymes may mask others
so that they block them and give false negative results
or vice versa, as is the case with AmpC enzymes and
ESBL enzymes where AmpC enzymes, unlike ESBLs,
are not inhibited by clavulanic acid but when both
types are present in the same isolate, the isolate may
not appear to be sensitive to clavulanic acid due to the
presence of AmpC enzyme and thought to be non
ESBLs producer, and that what Yang et al. [40]
mentioned in their research where they reported that
some K. pneumoniae strains had four enzymes, others
had three enzymes, and others contained only one
enzyme, and found that some of these enzymes were
AmpC and others were ESBLs.
Detecting the types of b-lactamase is necessary and
essential for identifying the bacteria that possess these
enzymes, controlling them and preventing or reducing
their spread [16,21]. However, this process is not that
easy because of the overlap of many factors and the
abundance of enzymatic types. Many methods have
been developed for the detection of these enzymes,
although many have proven effective, yet no method
have been developed to detect the types of these enzymes in different bacterial species with good
efficiency.
In the current study, five methods have been used to
detect and confirm the presence of ESBLs in Gram
negative enteric bacteria. Detection tests were performed on 23 isolates that gave a positive detection
result using CLSI method. Table 3 shows the results of
these confirmatory tests in comparison to CLSI
method, where they varied in detection rates they gave;
ceftazidime agar method was the most efficient method
followed by the double disk synergy method and
enzymatic disks method, while the combination disk
method and the modified 3D extract method had a
lower efficiency of detecting these enzymes.
Ceftazidime agar method was not included in the
published methods for detecting ESBLs enzymes as far
as we were aware, but we relied on the principle of the
cefoxitin agar method introduced by Nasim et al. [37]
to detect AmpC b-lactamases, and we modified it to be
used to detect ESBLs instead of AmpC enzymes. This
method has been shown to be efficient in detecting
ESBLs compared to other methods. We think that the

crude enzymatic extracts act by hydrolyzing ceftazidime in the media, allowing the sensitive isolate to
grow around the well, which is considered as an evidence for the presence of ESBLs enzymes and that it is
the mechanism used in the resistance.
For more certainty, the same method was used with
amoxicillin-clavulanic acid instead of ceftazidime,
where clavulanic acid inhibits ESBLs enzymes, if
present, in the enzymatic extracts and therefore the
sensitive isolate does not grow. Growth appearance
suggests the presence of enzymes that are not affected
by clavulanic acid such as AmpC enzymes or inhibitorresistant enzymes which hydrolyze amoxicillin and
allow the sensitive isolate to grow [15,34]. Although
this method is time-consuming and precision-requesting, it has proved its efficiency in detecting ESBLs
enzymes compared with other methods, as well as the
usage of crude enzymatic extracts which excludes
other resistance mechanisms like impermeability or
modifications in penicillin-binding proteins, and restricts it to b-lactamase enzymes, and this is what
distinguishes these methods from others.
The results also revealed the efficiency of double
disk synergy method where it gave a detection rate of
87% (Table 3). This method is one of the most widely
used methods in clinical laboratories to detect ESBLs
enzymes for its simplicity and ease of performing
[32,35]. However, it may sometimes give false results;
the distance between the two disks is of great importance, where Sanders et al., 1996 [30] indicated that the
distance between the disks should be 30 mm, while
Livermore and Brown, 2001 [34] reported that the
distance between the disks should be between 25 and
30 mm, this distance is so critical because it should
allow the antibiotic to diffuse to reach clavulanic acid
in order synergism to occur between them, which leads
to the expansion of inhibition zone to give the positive
result, if the distance is too large to allow such synergism to occur, the expansion does not occur and the
result is negative despite the presence of ESBLs
enzymes.
Enzymatic disks method is based on the same
principle as ceftazidime agar method, with the use of
disks instead of wells to contain the enzymatic extracts. It also proved to be of good efficiency, although
less than that of ceftazidime agar method, possibly
because the amount of extract taken by the disk is less
than that of the well. The combination disk method
detected ESBLs-producing isolates with a rate of
56.5% (Table 3), this method relies on the use of cefpodoxime instead of ceftazidime or cefotaxime. Some
studies have indicated that this antibiotic has a higher
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sensitivity to detect ESBL enzymes; the researchers
Carter et al. [32]; Livermore and Brown [34], for
instance, reported that this method has detected 100%
of ESBL-producing K.pneumoniae. The results of the
present study are not entirely consistent with that, we
found that this method has detected ESBL-producing
K. pneumoniae by 63.6% as shown in Table (3), and
this may be due to the difference in the disks used. We
used amoxicillin-clavulanic acid as a source of clavulanic acid instead of the cefpodoxime-clavulanic acid
disk, because of the lack of the latter.
The modified 3D extract method gave a similar
detection rate to that of the combination disk method
(56.5%). This method needs precision when performing and when results are read and interpreted, Thomson and Sanders [35] reported that a slight distortion in
the inhibition zone at the intersection of the slits is a
positive result, as the enzymatic breakdown of the
antibiotic depends on the amount of the enzyme present in the extract and the amount added, and should be
added accurately so that the quantity does not exceed
the size of the slit. In addition, some bacteria may
produce the enzymes in small quantities that they are
not enough to breakdown the antibiotic to give a positive result, especially in this method where the extracts
are added in the slits which represent more area than
the wells where the enzymes are concentrated in less
area so its effect appears even if its concentration is
low.
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5. Conclusion
ESBLs occurrence in Gram negative enteric bacteria was detected using CLSI method. Five confirmatory
detection methods were further used, in comparison to
CLSI method, in order to determine the most efficient
method. The present study found that ceftazidime agar
method is more efficient method than the others, followed by double disk synergy method and enzymatic
disk method. The results also indicated the efficiency
of cell-free enzymatic extracts dependent methods in
detecting ESBLs.
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